Date: 2012-05-08
Type of information: Grant
Company: Oramed Pharmaceuticals (Israel)
Investors: Office of the Chief Scientist (OCS -Israel)
Amount: NIS 2 million (approximately $540,000 or €414,000)
Funding type: grant
Planned used: The funds will be designated and used by Oramed Ltd. to support further R&D and clinical studies on its oral insulin capsule and oral GLP-1 analog from December 2011 to November 2012.
Others: Oramed Pharmaceuticals, a developer of oral delivery systems, has announced that its wholly owned Israeli subsidiary, Oramed Ltd., was awarded a government grant amounting to a net sum of NIS 2 million (approximately $540,000), from the Office of the Chief Scientist (“OCS”) at the Ministry of Industry, Trade and Labor of Israel.
Therapeutic area: Metabolic diseases
